Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271451 | 0.80 | MAP2K4 (0.52) | GSK3B | |
| SCHEMBL5678040 | 0.80 | GSK3B (0.54) | MAPTGSK3B | |
| SCHEMBL24076247 | 0.78 | PRMT5 (0.49) | PRMT5WDR77SMN1; SMN2ARPARP1 | |
| SCHEMBL24076862 | 0.77 | MAPT (0.47) | MAPTPRMT5WDR77SMN1; SMN2GSK3B | |
| SCHEMBL22552490 | 0.77 | PRMT5 (0.52) | PRMT5WDR77ARPARP1 | |
| SCHEMBL24782020 | 0.77 | PRMT5 (0.47) | PRMT5WDR77ARPARP1 | |
| SCHEMBL30168572 | 0.77 | MEN1 (0.47) | MAPTPRMT5WDR77SMN1; SMN2GSK3B | |
| SCHEMBL24076896 | 0.77 | MAPT (0.44) | MAPTPRMT5WDR77SMN1; SMN2GSK3B | |
| SCHEMBL24076884 | 0.77 | MEN1 (0.47) | MAPTPRMT5WDR77SMN1; SMN2GSK3B | |
| SCHEMBL29426569 | 0.77 | MAPT (0.44) | MAPTPRMT5WDR77SMN1; SMN2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | MAPT 1004/4885PRMT5 3337/4885WDR77 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.